JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

163.69 0.85

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

161.07

Max

165.02

Belangrijke statistieken

By Trading Economics

Inkomsten

182M

514M

Verkoop

264M

4.4B

K/W

Sectorgemiddelde

22.517

60.328

Winstmarge

11.778

Werknemers

93,000

EBITDA

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+38.37% upside

Dividenden

By Dow Jones

Volgende Winsten

5 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-9.4B

30B

Vorige openingsprijs

162.84

Vorige sluitingsprijs

163.69

Nieuwssentiment

By Acuity

72%

28%

329 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 apr 2026, 23:15 UTC

Belangrijke Nieuwsgebeurtenissen

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 apr 2026, 23:08 UTC

Winsten
Belangrijke Marktbewegers

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 apr 2026, 23:58 UTC

Winsten

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 apr 2026, 23:56 UTC

Winsten

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 apr 2026, 23:48 UTC

Marktinformatie

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 apr 2026, 23:42 UTC

Marktinformatie

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 apr 2026, 23:34 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 apr 2026, 23:30 UTC

Marktinformatie

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 apr 2026, 23:08 UTC

Marktinformatie

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 apr 2026, 23:02 UTC

Marktinformatie

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 apr 2026, 22:42 UTC

Marktinformatie

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 apr 2026, 22:10 UTC

Winsten

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 apr 2026, 22:09 UTC

Winsten

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 apr 2026, 21:56 UTC

Winsten

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 apr 2026, 21:55 UTC

Winsten

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 apr 2026, 21:44 UTC

Winsten

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 apr 2026, 21:43 UTC

Winsten

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 apr 2026, 21:41 UTC

Winsten

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

27 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 apr 2026, 20:39 UTC

Winsten

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

38.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 224.54 USD  38.37%

Hoogste 255 USD

Laagste 185 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

329 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat